Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ADI-PEG 20 |
Synonyms | |
Therapy Description |
Pegargiminase (ADI-PEG 20) is polyethylene glycol-conjugated arginine deiminase which degrades arginine, thereby depleting arginine and potentially inhibiting growth of arginine-dependent tumor cells (PMID: 22864522, PMID: 30796035, PMID: 32409304). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADI-PEG 20 | Pegargiminase|ADI-PEG20|pegylated arginine deiminase | Pegargiminase (ADI-PEG 20) is polyethylene glycol-conjugated arginine deiminase which degrades arginine, thereby depleting arginine and potentially inhibiting growth of arginine-dependent tumor cells (PMID: 22864522, PMID: 30796035, PMID: 32409304). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02101593 | Phase I | ADI-PEG 20 | Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer | Completed | USA | 0 |